Precision lead placement could boost heart failure device success

NCT ID NCT03280862

Completed Disease control Sponsor: Aarhus University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether placing the left ventricle lead of a cardiac resynchronization therapy (CRT) device at the heart's latest electrical activation spot improves outcomes. It included 1,000 heart failure patients with bundle branch block. The goal was to see if this targeted approach reduces death or unplanned heart failure hospitalizations compared to standard lead placement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cardiac resynchronization therapy (CRT) device implantation
What this could lead to: If successful, this approach could reduce deaths and hospitalizations for heart failure patients by improving how the device is placed.
What could go wrong: The trial is completed but results are not yet widely confirmed. Targeted placement may increase procedure time, infection risk, or radiation exposure, and might not benefit all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRANCH BLOCK, BUNDLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bundle branch block, familial isolated complete right heart failure progressive familial heart block, type 1A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRANCH BLOCK, BUNDLE HEART FAILURE

Contacts and locations

Locations

Aalborg University Hospital

Aalborg, 9000, Denmark
Aarhus University Hospital

Aarhus, 8200, Denmark
Gentofte University Hospital

Gentofte Municipality, 2900, Denmark
Odense University Hospital

Odense, 5000, Denmark
Rigshospitalet

Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.